RDS secures 14M to scale MultiSense remote patient monitoring patch

French medtech startup RDS has raised €14 million in Series A funding to accelerate the industrialisation and commercialisation of its flagship solution – MultiSense. The round was led by the SPI fund managed byBpifrance, with participation from Critical Path Ventures, MACSF, Capital Grand Est, and other existing backers.
The new capital brings RDS’s total financing to €28 million, combining venture funding with public support from the France 2030 investment plan and the European Union.
Expands access to remote patient monitoring
MultiSense® is a CE-marked, class IIa medical device designed to continuously track key physiological parameters in hospitals and at home. Already deployed in 15 hospitals across France, Belgium, and Germany, the connected patch has gained traction by being added to the purchasing lists of major French hospital networks RESAH and UniHA.
Clinically validated and recognised for its accuracy, the device addresses rising demand for reliable, long-term patient monitoring. Hospitals face increasing pressure to shorten stays and manage post-operative recovery more efficiently, while home-based monitoring helps ease healthcare system burdens. These trends, reinforced by the Covid-19 pandemic, have accelerated adoption of solutions like MultiSense.
Driving European growth and industrial scale-up
With the fresh investment, RDS aims to ramp up manufacturing of MultiSense in France and strengthen its European footprint. The company plans to expand in France, Germany, and other key markets, while creating several hundred jobs by 2035.
Funds will also be directed toward industrial operations, including scaling production and refurbishing capacity to meet growing demand. In parallel, RDS will initiate new clinical trials to support reimbursement applications across Europe, a critical step for widespread adoption of its technology.
To bolster its leadership, RDS has welcomed Laurent Monnin of Bpifrance and Nicolas Foessel of Critical Path Ventures to its strategic board. Their expertise is expected to guide the company through its next stage of growth and international expansion.
Preparing for the US market entry
Beyond Europe, RDS is laying the groundwork for a transatlantic expansion. The company is preparing to start the FDA registration process, targeting a US launch in 2028. This move positions RDS to enter a vital signs monitoring market projected to reach $15 billion in 2025, with annual growth of 15% through 2030.
By bridging hospital and home care, MultiSense is well placed to capture part of this growth. Its role in reducing hospital stays, improving recovery outcomes, and enabling continuous monitoring aligns with healthcare’s global shift toward more patient-centered, cost-effective care.
“This investment gives us the means to ramp up our sales growth in Europe, consolidate the clinical and health economic value of MultiSense, and get ready for market launch in North America,” said Elie Lobel, CEO of RDS.“These funds mean we can roll out our solution more widely to hospitals, expand its positive impact for patients and care teams, and provide reliable, continuous, clinically validated remote monitoring to as many facilities as possible. The funds raised are a testament to our investors’ enduring confidence in this project and the team.”
“France 2030 is proud to have supported this project since 2020 and to work today with SPI on the rapid industrialization and effective deployment of the solution for the benefit of patients. RDS’ story clearly shows how France 2030 is capable of transitioning a project from the lab stage to becoming an international champion,” said Bruno Bonnell, Secretary General for Investment, in charge of France 2030.
“We are delighted to be supporting RDS in this critical phase of its development,” said Magali Joëssel, director of the SPI fund at Bpifrance. “This funding gives the company the means to become a leading player in post-operative remote monitoring through MultiSense, and a pioneer in the medicine of the future. By scaling the manufacturing of its solution, RDS fully embodies the principle of the SPI fund: funding the industrialization of innovative technologies that will bring growth and jobs to France.”“We believe that the key to transforming the healthcare system is useful innovation and industrial ambition,” said Nicolas Foessel of Critical Path Ventures. “With our investment in RDS, we are backing a team that combines technological excellence with clinical impact and a long-term vision for medicine, with emphasis on a more preventive, smoother and human approach. MultiSense exemplifies this positioning, enabling continuous monitoring and meeting patients’ particular needs away from the hospital setting.”“The funding provided by SPI and Critical Path Ventures is a real asset for RDS, which will be able to ramp-up activities after a launch phase to which MACSF and Capital Grand Est have contributed,” said Jean-François Rax, partner at Capital Grand Est.
“ERAS (Enhanced Recovery After Surgery) studies have shown the importance of short hospital stays, even after a major surgery. However, the use of these protocols remains limited because surgeons have to engage their responsibility. The MultiSense patch offers an ideal solution: faster patient discharge and a more effective monitoring of vital signs than in hospital, with considerable medical and economic benefits expected. This is a major challenge for the sustainability of our healthcare system,” concluded Jacques Marescaux, professor of surgery, president and founder of IRCAD, and member of RDS’ Scientific Board.